The molecular mechanism underlying the metabolic defect in phenylketonuria (PKU) patients carrying the V388M missense mutation of the phenylalanine hydroxylase (PAH) gene has been characterized. An in vitro prokaryotic expression system has been used to produce both the wild-type and the mutant form of the human PAH (hPAH) protein. The recombinant enzymes, obtained as fusion proteins, were purified by immobilized metal affinity chromatography and recovered in high yields. The wild-type hPAH possessed a high specific activity and its kinetic properties were the same as those reported for the enzyme isolated from human liver and other recombinant wild-type hPAH enzymes. The recombinant V388M mutant form exhibited a reduced specific activity equivalent to 30% of the wild-type hPAH enzyme when assayed using the synthetic cofactor (6-methyltetrahydropterin). Lower values were obtained (23 and 19%) when the mutant enzyme was assayed with the natural cofactor ((6R)-tetrahydrobiopterin) and different concentrations of L-phenylalanine. The enzyme kinetic studies of the V388M mutant protein revealed that this enzyme was a kinetic variant form of hPAH with a reduced affinity for L-phenylalanine and for the natural cofactor ((6R)-tetrahydrobiopterin). The residual activities determined for the V388M form of hPAH were compatible with the phenotype presented by the PKU patients harboring the V388M mutation in the PAH gene.
Phenylalanine hydroxylase (PAH; EC 1.14.16.1) is a hepatic, nonheme, iron-dependent metalloenzyme which catalyzes the hydroxylation of phenylalanine (Phe) to tyrosine (Tyr). Deficiency of PAH enzymatic activity is the most common cause of human hyperphenylalaninemia (HPA). More than 300 different mutations in the coding sequence of the human PAH gene (symbol PAH) are associated with variant forms of the disease (PAH Mutation Analysis Consortium Database; http://www.mcgill.ca/pahdb). The mutations lead to a variety of clinical and biochemical phenotypes with different degrees of severity, classified as classical phenylketonuria (PKU), mild PKU, and non-PKU (1) . In 1991, Okano et al. (2) reported genotype-phenotype correlation in PKU. Since that time a number of studies have been published reporting the correlation of many genotypes and a broad spectrum of phenotypes in patients with elevated blood Phe levels in various populations. While most genotypes studied by eukaryotic or prokaryotic in vitro expression have allowed the correct prediction of the biochemical phenotype (3), some phenotypes appear to be inconsistent with the results of in vitro expression analyses.
In Portugal, the V388M mutation is the third most common mutation in the PAH gene. This DNA aberration was found in 20 of the 225 mutant chromosomes studied (8.9% of the mutant alleles), on the haplotype 1.7 background (4). The V388M missense mutation (c. 1162 G3 A) is a G to A transition in the second base of codon 388, at cDNA position 1162 (exon 11). This mutation eliminates a BsaAI restriction site in exon 11 and provides the basis for an assay, which has been used to screen for this mutation in the Portuguese PKU population (5) .
When expressed in an eukaryotic expression system (6), the V388M mutant enzyme presented a high residual activity (43% of the normal PAH). However, the metabolic phenotype of the Portuguese PKU patients harboring the V388M allele did not correlate with the referred "predicted in vitro residual enzyme activity" (PRA), as was reflected by Phe pretreatment values higher than those expected from the PRA. This discrepancy could be explained by an overestimation of the PAH activity when determined in transfected mammalian cells as described by Okano et al. and Svensson et al. (2, 7) . Moreover, the V388M mutant protein has been shown to be one of the few stable mutant hPAH proteins that, when expressed in mammalian cells, had normal levels of PAH immunoreactive protein.
The observed decrease in PAH specific activity, while protein levels remain normal, implicates this mutation in affecting amino acid residues important for catalytic or regulatory functions (8) . The detailed study of such mutations will contribute to an understanding of their effects on PAH structure and function, such as that reported for the D143G mutation (9) .
The studies described were performed in order to reevaluate the activity of the V388M mutant protein and to elucidate the possible role of residue V388 in PAH enzymatic functions. For this purpose a prokaryotic expression system in which the wild-type PAH is expressed at high levels in Escherichia coli as a fusion protein was used. The expression system was validated through a comparative study with the wild-type enzyme and two other well-known and documented mutant enzymes, namely, the I65T (10) and R261Q mutant proteins (2) . The resulting biochemical characterization shows that the V388M mutant protein has a lower catalytic activity than previously described when expressed in the eukaryotic system (6) . Additionally, a lower affinity for the natural cofactor (6R)-tetrahydrobiopterin (BH 4 ) was observed. These data are in full accordance with the metabolic phenotype described for the PKU patients harboring the V388M mutant allele and show that the functional effects of this mutation on PAH, produced as 6 ϫ His fusion protein in E. coli, are on its specific activity and kinetic properties.
MATERIALS AND METHODS

Directed Mutagenesis of hPAH cDNA
The full-length human PAH cDNA was excised from phPAH247 (11) with the restriction endonuclease EcoRI. The EcoRI fragment of PAH was purified and ligated into the EcoRI digested and dephosphorylated DNA of bacteriophage M13mp18. An oligonucleotide-directed mutagenesis kit from Amersham (Sculptor, Piscataway, NJ) was used to introduce the desired mutations in the PAH sequence, using mutagenic oligonucleotides (Table 1) . Mutant plaques positive for the respective mutations were screened by PCR amplification using primers 1ANcoI and 3B65TaqI (I65T mutation), primers 5AMspI and B861 (R261Q mutation) and primers 8A299HindIII and UPM13R (V388M mutation) (Table 1) . DNA sequencing verified the introduction of the desired mutations and excluded additional mutations due to misincorporations. 
PAH Expression Vector
The plasmid pTrcHis (Invitrogen, Carlsbad, CA) was used to express the wild-type and the mutant PAH enzymes in the prokaryotic system. The cDNA containing the full-length human PAH (hPAH) coding sequence and the resulting mutant PAH sequences were excised from the plasmid phPAH247 and recombinant M13mp18 bacteriophage DNAs by endonuclease digestion with EcoRI. These fragments were subsequently digested with SmaI. SmaI cuts within the 5Ј-untranslated region of the PAH cDNA at position 211. This resulting 2237-bp fragment contains the entire open reading frame and the 3Ј-untranslated region, but retains only 12 bases 5Ј to the start codon. This fragment was rendered blunted ended by the action of T4 DNA polymerase, resolved by agarose gel electrophoresis, and purified. The blunt-ended fragment was ligated into the BamHI site of pTrcHisB vector, which had been previously digested and blunted using T4 DNA polymerase. An in-frame sequence encoding a fusion peptide, i.e., 6 ϫ His, the recognition sequence for the restriction protease enterokinase (EK), and PAH was obtained. The resulting recombinant plasmids, containing the hPAH sequences in a sense orientation, were used to transform competent TOP10 cells (Invitrogen).
Expression of Recombinant PAH
For the production of recombinant hPAH enzyme, fresh overnight cultures were diluted 1:100 into 50 ml to 1 L of LB medium containing 50 g/ml of ampicillin. Cells were grown at 37°C, with expression induced by the addition of 1 mM isopropylthio-␤-D-galactoside (IPTG) when the A 600 was about 0.6. Simultaneously, 0.1 mM ferrous ammonium sulfate (Fe 2ϩ ) was added to the culture. Kinetic induction studies were performed with an incubation period of 12 h, with samples collected at 0, 1, 2, 3, 4, 5, and 12 h after induction. For recombinant protein purification, induction was performed for a period empirically determined to maximize the prokaryotic expression of PAH enzyme form under investigation. Bacterial pellets were collected by centrifugation at 4000g for 10 min at 4°C. The pellets were stored frozen at Ϫ20°C until used. The bacterial pellets were resuspended (40%, w/v) in lysis buffer (50 mM potassium phosphate; 300 mM NaCl, pH 7.8; and 10% glycerol) containing 1 mM phenylmethanesulfonyl fluoride (PMSF) and 1 mg/ml lysozyme. After a 30-min incubation at 4°C, cells were disrupted by passage through a Carver Press (Model C, from F. S. Carver, Inc, Wabash, IN) at 4000 psi. The crude extract was then centrifuged at 10,000g at 4°C for 20 min. The concentrations of imidazole and ␤-mercaptoethanol (␤-ME) in the supernatants were adjusted to 10 mM and processed immediately.
Purification of Recombinant hPAH
The fusion proteins expressed in E. coli were purified by immobilized metal affinity chromatography (IMAC) using a Ni-chelating resin (Ni-NTA-resin, Qiagen, Valencia, CA) in a batch procedure at 4°C. The cell lysates were applied to the Ni-NTA-resin preequilibrated in lysis buffer containing 10 mM imidazole and stirred for 1 h at 4°C. The resin was washed at 4°C, 5 min each, with four 10 bed vol of lysis buffer, 20 mM in imidazole; one 10 bed vol of lysis buffer containing 50 mM imidazole; and three 1 bed vol of lysis buffer, 150 mM in imidazole. The fusion proteins were eluted with 6 ϫ 0.5 bed vol of lysis buffer, 250 mM in imidazole. The isolated enzymes were dialyzed overnight at 4°C against a buffer containing 20 mM Tris-HCl, pH 7.5; 100 mM KCl; and 0.1 mM EDTA.
Cleavage of the Fusion Proteins
The leader fusion peptide (6 ϫ His) was excised from the recombinant fusion protein by cleavage with EK (New England Biolabs, Inc., Beverly, MA). In this reaction, 50 g of purified protein was incubated with 1 unit of EK in 200 mM Tris-HCl, pH 7.4; 50 mM NaCl; and 2 mM CaCl 2 (ratio EK:fusion protein about 1:30) for 12 h at 16°C.
Denaturing Polyacrylamide Gel Electrophoresis and Western Blotting
Enzyme samples were electrophoresed in 10% polyacrylamide gels containing SDS according to Laemmli (12) . The gels were stained with Coomassie brilliant blue R. After destaining, protein purity was assessed by densitometry scanning, followed by analysis using Image Master1D (version 2.0) software (Pharmacia, Kalamazoo, MI).
Immunoblotting was performed using Ni-NTA alkaline phosphatase conjugates (Qiagen).
Native Polyacrylamide Gel Electrophoresis
To determine the oligomeric structure of the purified recombinant hPAH proteins, samples were electrophoresed in 10 and 12% polyacrylamide gels according to Laemmli (12) , but in the absence of SDS and reducing agents. Following the resolution of the hPAH protein samples and molecular weight markers at the two acrylamide concentrations, mobilities were determined and used for the construction of Ferguson plots according to the method of Gallagher (13) .
Protein Measurements
Protein concentrations were determined colorimetrically by the method of Bradford (14) . The purified enzyme was measured by its absorbance at 280 nm using the absorption coefficient A 280 (1 mg ml Ϫ1 cm Ϫ1 ) ϭ 1.0 (15).
Assay of PAH Activity
Enzyme assays were essentially performed as described by Martinez et al. (15) with minor modifications. PAH activity was assayed with each of the two cofactors, the natural cofactor (BH 4 ) or the synthetic cofactor [6-methyltetrahydropterin (6-MPH 4 )], in a final volume of 250 l, using 5 g of the purified enzyme. The term "activated enzymes" refers to PAH samples incubated for 4 min at 25°C with L-Phe. In the nonactivated reaction, the enzyme was always added as the final component to the complete reaction mixture. After a reaction period of 1 min, the reaction was terminated by the addition of 500 l of cold 12% (w/v) trichloroacetic acid (TCA). After the precipitation of proteins at Ϫ20°C and centrifugation, the tyrosine formed was measured by the colorimetric nitrosonaphthol assay (16) . The assays were performed in triplicate on freshly isolated protein preparations. The steady-state kinetic data, including the Hill constant h, were analyzed using the MicroMath Scientist version 2.01 software from MicroMath, Inc. (Salt Lake City, UT)
N-terminal Sequence Analysis
The N-terminal amino acid sequence of the purified hPAH preparations was determined using an Applied Biosystems Protein Sequencer (Foster City, CA).
RESULTS
Expression and Purification of PAH Fusion Proteins
The wild-type and mutant hPAH recombinant proteins were expressed in E. coli. The kinetics of induction revealed that maximum yields were achieved 4 h after IPTG induction for the mutant recombinant proteins and 5 h after induction for the wild-type form. At these time points, the 6 ϫ His mutant and wild-type proteins represented about 0.6 and 2.7% of total soluble proteins, respectively. Western blot analysis of the crude cell extracts did not show significant levels of these proteins in the insoluble fraction.
Using the chromatographic conditions described, 4 -5 mg of 95% pure wild-type enzyme and 0.5-0.7 mg of about 80% pure mutant proteins per liter of culture medium were obtained (Fig. 1, Table 2 ). The molecular weight of the cloned fusion enzyme (monomer) was determined to be 55 kDa by denaturing polyacrylamide gel electrophoresis. Based upon the estimated size of the fusion peptide of 3 kDa, a size of about 52 kDa could be deduced for the hPAH protein, which was in agreement with the size reported for the nonphosphorylated human liver enzyme (17, 18) . When the fusion protein was cleaved by enterokinase, the N-terminal amino acid sequence of the purified recombinant hPAH was identical to that predicted from the inserted cDNA sequence, i.e., NH 2 -DRGASMSTAVL (the underlined amino acid is the initiator methionine).
The oligomeric composition of the recombinant wild-type enzyme was determined by nondenaturing polyacrylamide gel electrophoresis (12, 13) . The molecular weights of the enzymes were calculated from a log plot of molecular weight (MW) against R f . The molecular weights of the two major forms of the enzyme were estimated to be about 200 and 100 kDa corresponding to tetramers and dimers, respectively.
Kinetic Properties of Recombinant hPAH
The specific activities of the purified recombinant hPAH fusion proteins are presented in Table 3 . The wild-type form revealed high catalytic activity (2489 nmol Tyr formed min Ϫ1 mg Ϫ1 ). The kinetic properties of the purified recombinant 6 ϫ His wild-type hPAH are summarized in Table 4 . These data are compared with those reported for PAH isolated from human liver (18) and with other recombinant hPAH proteins expressed in prokaryotic systems (15) . Table 3 .
The digestion of the 6 ϫ His PAH fusion proteins with enterokinase ( Fig. 1 ) was almost complete (Ͼ90% cleavage). The purified recombinant hPAH enzymes obtained, cleaved and free of the 6 ϫ His fusion peptide, had the same catalytic activity as the purified fusion forms of the recombinant hPAH proteins.
When assayed under standard conditions, the V388M recombinant mutant enzyme had 30% of the wild-type 6-MPH 4 -dependent activity (at 1 mM L-Phe, 500 M 6-MPH 4 ) and 23% of the wild-type BH 4 -dependent activity (at 1 mM L-Phe, 75 M BH 4 ). At lower concentrations of L-Phe (100 M), the BH 4 -dependent activity decreased to 19% of that of the wild-type enzyme. The ratio of 6-MPH 4 -dependent activity/BH 4 -dependent activity was 1.9 for V388M protein versus 1.4 for the wild-type hPAH enzyme. When the concentration of the cofactor was kept constant (75 M), the V388M protein exhibited a slightly lower affinity for L-Phe, than did the wildtype enzyme (Fig. 2, Table 5 ). A slight substrate inhibition was observed for the wild-type enzyme at concentrations Ͼ1 mM L-Phe, while the mutant enzyme was inhibited at concentrations above 500 M L-Phe. No substrate inhibition was observed in the presence of the synthetic cofactor (6-MPH 4 ) at concentrations of L-Phe up to 20 mM. The kinetic properties of the V388M mutant hPAH enzyme are presented in Table 5 . The apparent K m values for the natural cofactor (BH 4 ) was 82 M and the S 0.5 for L-Phe (with the natural cofactor) was 298 M, indicating that positive cooperativity of L-Phe binding was preserved. The effect of preincubation with L-Phe on the catalytic activity was determined for the wild-type and the V388M mutant form (Table 5) of the recombinant hPAH enzyme. In the presence of 6-MPH 4, the ratio of activation of the V388M enzyme by L-Phe was similar to the wild-type form, while in the presence of BH 4, a value of 1.7 for the V388M mutant protein versus 2.1 for the wild-type hPAH was observed. 
DISCUSSION
Expression of recombinant mutant hPAH proteins in mammalian cell systems has been discussed to be the most reliable in vitro system that best reflects the human in vivo situation (19) . However, the difficulty of expressing stable forms of hPAH mutant proteins in eukaryotic cells has impaired the characterization of those enzymes. Currently, only 31 of the more than 300 different mutation reported to the PAH Mutation Analysis Consortium have been expressed in mammalian cells, with their relative enzymatic activities determined. Additionally, the relatively large amounts of purified protein required for the detailed biochemical characterization of normal and mutant PAH proteins compromises the possibility to perform such characterizations quickly and economically without the use of overexpression, which is possible in prokaryotic systems. Recombinant wild-type and mutant forms of hPAH have been expressed in E. coli as nonfusion proteins (20, 21) , as well as fusion products with the maltose binding protein (MBP) (8, 15) . The recombinant PAH enzymes produced in the prokaryotic cells have allowed the detailed biochemical characterization of the normal and mutant forms of the enzyme. In the case of the V388M mutation, the data obtained more accurately reflected the phenotype of patients harboring this mutation than have the eukaryotic expression data (6) .
To perform a detailed study of the functional properties of the V388M mutant enzyme compared with those of the wild-type recombinant hPAH, the prokaryotic expression vector pTrcHis was used. In this system the recombinant proteins were produced as fusion products with the 6 ϫ His peptide. The use of the fusion peptide provided a means to limit proteolysis and simultaneously to allow an easy singlestep purification of the expressed proteins, based upon the high affinity of the 6 ϫ His sequence for Ni 2ϩ -chelating resins. Also, since the leader peptide (6 ϫ His) is short, compared with other fusion partners (e.g., maltose binding protein), protease cleavage is in many cases not necessary for functional assays of the recombinant fusion proteins (22) . The use of the pTrcHis vector and TOP10 host cells allowed the recovery of undegraded recombinant hPAH proteins in high yield (up to 2.7% of total soluble cellular proteins). The IMAC purification method enabled the isolation of highly purified (Ͼ95%) homogeneous hPAH enzyme preparations with high catalytic activity (2489 nmol Tyr min Ϫ1 mg Ϫ1 ) and which were not altered by enterokinase cleavage.
A comparative kinetic study was performed to determine whether the recombinant wild-type 6 ϫ His hPAH enzyme produced in this system shared similar properties with the human liver enzyme and with other recombinant hPAH proteins produced in other expression systems. The values for the apparent K m for Phe in the presence of synthetic or natural cofactor (6-MPH 4 or BH 4 , respectively), as well as the apparent K m for the natural and the synthetic cofactors (Table 4) , were comparable to those of the purified human enzyme. It was interesting to observe that the 6 ϫ His hPAH had apparent K m values comparable with those of the purified recombinant protein (without the fusion partner MBP) obtained by Martinez et al. (15) . These results indicated that the 6 ϫ His tag did not affect the accessibility of the substrates to the active site(s) of the enzyme.
Although the 6 ϫ His hPAH mutant forms were expressed at lower levels than the wild-type form (0.3-0.6% of total soluble cellular proteins), the relative activities determined for the I65T and R261Q mutant proteins were in full agreement with the previously published data for PAH expression in eukaryotic (COS) cells (Table 3) . As expected, the isolated stable form of the V388M protein exhibited a relative enzymatic activity lower than that described when this mutant form was expressed in COS cells (6) . When lower concentrations of L-Phe were used in the enzyme assays (100 M) the residual activity of V388M protein was lower (19%) than the activity obtained using 1 mM of L-Phe (23%). This phenomenon was previously observed by Knappskog et al. (9) and illuminates the need to avoid enzymatic assays performed with a single high substrate concentration and the need to use physiological concentrations of L-Phe. The use of high standard in vitro assay conditions (e.g., 1 mM L-Phe and 75 M BH 4 ) was probably one of the reasons why some of the mutant hPAH proteins expressed in eukaryotic cells exhibited unexpectedly high residual enzymatic activity.
Efforts have been made to predict metabolic HPA phenotypes from the known genotypes (23) . A residual activity of about 15% (2) was proposed to represent the boundary between classical PKU and milder forms of HPA. Using this criterion in the homoallelic genotype, the V388M mutation, with a residual enzymatic activity of 23-30%, would suggest a mild form of HPA in such individuals. The "functionally hemizygous" genotype, V388M/null (24) , would suggest a residual activity of 12-15%, leading to a classical PKU phenotype. Using this classification system, a good correlation between the genotype and the level of pretreatment serum phenylalanine (results in press) has been found in the Portuguese patients harboring the V388M mutant allele.
According to Kaufman (16) , the 6-MPH 4 -dependent activity is not affected by the enzyme activation state, whereas the BH 4 -dependent activity is affected by the PAH state of activation. Thus, the ratio of 6-MPH 4 /BH 4 -dependent activities is an index of the state of activation of the enzyme, with a higher ratio indicating a lower activation state. As revealed by the analysis of the PAH mutant proteins characterized previously, the increased activation state of some mutant PAH enzymes seemed to reflect a conformational change associated with aggregation. The V388M protein presented a ratio of 6-MPH 4 / BH 4 -dependent activities of 1.9 versus 1.4 for the wild-type form, implying a decreased activation state of this mutant enzyme. This ratio is in accordance with the values founded for the relative specific activities (30% for 6-MPH 4 -dependent activity and 23% for BH 4 -dependent activity) and suggests that this mutation is not associated with an increased tendency of the V388M protein for aggregation.
The enzyme kinetic studies revealed that the V388M mutant protein represents a kinetic variant form of hPAH. The apparent K m for BH 4 was 3.7-fold higher than for the wild-type hPAH enzyme and the apparent K m for L-Phe (with the natural cofactor) was twice the value determined for 6 ϫ His wildtype hPAH. Accordingly, the V388M mutant protein shows a decreased affinity both for the natural cofactor (BH 4 ) and for L-Phe, with the decreased affinity being more pronounced for the cofactor. As indicated by the ratio of activation by L-Phe (Table 5) , the V388M protein was found to be less susceptible to L-Phe activation than the 6 ϫ His wild-type form of the enzyme in the presence of the natural cofactor. The positive cooperativity of L-Phe binding was preserved indicating normal regulatory properties for the V388M enzyme, which was to be expected since the affected codon is located in the catalytic C-terminal domain of the enzyme.
Based upon the expression of normal amounts of immunoreactive V388M mutant protein in the eukaryotic cells, Desviat et al. (6) excluded instability and excessive degradation of the mutant protein as a molecular explanation for the PKU phenotype, thus suggesting an effect in the kinetic properties as revealed by this study. The V388 residue is located on the catalytic domain of hPAH in a hydrophobic region. We have shown that the V388M mutation directly affects the protein affinity for the cofactor. This residue does not belong to the putative pterin binding motif (His 263-His 289) (25) , but it is located on the ␤6 strand immediately after the mobile loop (residues 378 -381) that covers the channel which leads to the active site (26) . The substitution of Val by Met would not be predicted to perturb the structure of the enzyme. However, the V388 residue, which is conserved between human phenylalanine hydroxylase and rat tyrosine hydroxylase, appears to be important to the affinity of the enzyme for both the cofactor and the substrate and probably contributes to form the shape of the referred channel.
In conclusion, our investigation contributes to the accumulating knowledge concerning enzymatic phenotypes resulting from mutations in the PAH gene. Additionally, our study emphasizes that the structure of the PAH enzyme is very sensitive to single point mutations throughout the enzyme and that the study of naturally occurring PAH mutations is a useful tool to gain further insight into the structure/ function relationship of this enzyme.
